"paper"

A retrospective, multicentre, cross-sectional study aiming to evaluate the performance of cortical lesions and the central vein sign in differentiating multiple sclerosis from other conditions with brain white matter lesions.

This study presents the results of a clinical trial investigating whether apixaban, compared to aspirin, would be associated with reduced risk of stroke or systemic embolism, with a tolerably low risk of major bleeding.

Our Paper of the Month for November is a meta-analysis investigating the safety and efficacy of oral anticoagulation for prevention of major cardiovascular events in patients with atrial fibrillation and previous spontaneous intracranial haemorrhage.

Our Paper of the Month for October 2023 is a multicentre, prospective, randomised clinical trial investigating whether transdermal nicotine may have a disease-modifying effect in early, therapy-naïve Parkinson's disease.

Our paper of the month presents the results of a randomised trial assessing AXER-204, a soluble decoy fragment of NgR1 able to block the action of three inhibitors of the axonal growth in individuals with chronic traumatic cervical SCI.

Our paper of the month is a phase 3, double-blind, multicentre, trial investigating the efficacy and the safety of vorasidenib, a dual inhibitor of the IDH1 and IHD2 enzymes, in patients with residual or recurrent IDH mutant grade 2 gliomas.

This month we have selected two papers of the month, reporting the results of two randomised, double-blind, placebo-controlled, phase III trials investigating potential therapies for generalised Myasthenia Gravis.

Co-Chair of the EAN Scientific Panel on Dementia and Cognitive Disorders answers three key questions about a groundbreaking Alzheimer study.

Our paper of the month is a phase 1b, randomised, multicentre, placebo-controlled trial, which aims to investigate the safety, pharmacokinetics, and effects of MAPTRx in patients with mild Alzheimer's.

Our April paper of the month investigates the association between focal epilepsy and risk of incident dementia compared with patients with stroke or migraine and with healthy controls.

On the occasion of the Brain Awareness Week, the European Brain Council and the European Federation of Pharmaceutical Industries and Associations have launched the RETHINKING Alzheimer’s disease White Paper.

Our paper of the month presents the results of a prospective, double-blind, randomised, sham-controlled trial involving 16 centres and investigating the safety and efficacy of unilateral FUSA of the globus pallidus internus in patients with medication-refractory idiopathic PD.

Our February Paper of the Month is a narrative review focusing on epidemiology, pathophysiology and treatment of secondary headache following SARS-COV-2 infection and vaccination, and on the impact of COVID-19 pandemic on primary headache disorders.

Our paper of the month is a retrospective nationwide cohort study that was carried out to determine the clinical sequelae of long covid for a year after infection in patients with mild disease, and to evaluate its association with age, sex, SARS-CoV-2 variants, and vaccination status.

Our paper of the month reports the results of the ENCHANTED 2/MT trial, performed in 44 Chinese hospitals to compare more intensive with less intensive blood pressure management after successful endovascular thrombectomy.